Actinogen Medical Financial Results

• Significant progress was achieved immediately following the reporting period, with the FDA and MHRA granting regulatory approval of the Company’s Phase II trial, XanADu. • Actinogen also expects regulatory approval from the Australian TGA over the coming weeks. • Regulatory approvals provide strong endorsement of the development of Xanamem™ and underscore the depth and quality of Actinogen's exi